Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

KNSA stock hub

Kiniksa Pharmaceuticals International, plc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KNSAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KNSA

In the news

Latest news · KNSA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E46.2

P25 12.6P50 18.3P75 33.7

Trailing P/E64.6

P25 15P50 23.3P75 38.5

ROE13.7

P25 -106.6P50 -46.9P75 -3.1

ROIC41.5

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KNSA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

237

Groups with data

Currency

USD

Showing 237 of 237 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001730430
Company name	Kiniksa Pharmaceuticals International, plc
Country	United Kingdom
Country code	US
Cusip	G5269C101
Employees	366
Employees Change	51%
Employees Change Percent	16.19
Enterprise value	$4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-05-24
Isin	GB00BRXB0C07
Last refreshed	2026-05-10
Market cap	$4.5B
Market cap category	Mid-Cap
Price	$58.6
Price currency	USD
Rev Per Employee	2,060,232.24x
Sector	Healthcare
Sic	2834
Symbol	KNSA
Website	https://www.kiniksa.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.62%
EV Earnings	55.43x
EV/EBIT	43.44x
EV/EBITDA	42.67x
EV/FCF	24.66x
EV/Sales	5.37x
FCF yield	3.64%
Forward P/E	46.23x
P/B ratio	7.13x
P/E ratio	64.56x
P/S ratio	5.98x
PEG ratio	1.19x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	12.36%
EBITDA Margin	12.58%
FCF margin	21.78%
Gross margin	54.65%
Gross Profit	$412.1M
Gross Profit Growth	57.49%
Gross Profit Growth Q	54.86%
Gross Profit Growth3 Y	30.25%
Net Income	$73.1M
Net Income Growth Q	164.57%
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Net Income Growth3 Y	-28.07%
Pretax Margin	14.06%
Profit Margin	9.69%
Profit Per Employee	$199,612
Profitable Years	1
ROA	8.18
Roa5y	-6.61
ROCE	13.94
ROE	13.74
Roe5y	0.96
ROIC	41.5
Roic5y	-1,447.9

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	119.02%
Cagr3y	62.35%
Cagr5y	31.99%
EPS Growth Q	145.5
EPS Growth Quarters	5
EPS Growth Years	1
EPS Growth3 Y	-31.08
FCF Growth	275.52%
FCF Growth Q	125.14%
FCF Growth3 Y	62.52%
OCF Growth	276.73%
OCF Growth Q	124.87%
OCF Growth3 Y	62.88%
Revenue Growth	56.71x
Revenue Growth Q	55.51x
Revenue Growth Quarters	10x
Revenue Growth Years	4x
Revenue Growth3 Y	47.22x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.06
Assets	$825.3M
Cash	$468.1M
Current Assets	$594.2M
Current Liabilities	$156.6M
Debt	$9M
Debt EBITDA	$0.09
Debt Equity	$0.01
Debt FCF	$0.05
Equity	$605.7M
Liabilities	$219.6M
Long Term Assets	$231.1M
Long Term Liabilities	$63M
Net Cash	$459.1M
Net Cash By Market Cap	$10.18
Net Cash Growth	77.64%
Net Debt EBITDA	$-4.84
Net Debt Equity	$-0.76
Net Debt FCF	$-2.8
Tangible Book Value	$590.7M
Tangible Book Value Per Share	$8.02
WACC	5.19

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.79
Inventory Turnover	7.18
Net Working Capital	$-27.4M
Quick ratio	3.14
Working Capital	$437.6M
Working Capital Turnover	$2.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-11.98%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	118.9%
200-day SMA	41.14
3Y total return	328.05%
50-day SMA	47.79
50-day SMA vs 200-day SMA	50over200
5Y total return	300.55%
All Time High	58.85
All Time High Change	-0.42%
All Time High Date	2026-05-08
All Time Low	5.01
All Time Low Change	1,069.66%
All Time Low Date	2019-10-17
ATR	2.36
Beta	0.17
Beta1y	-0.36
Beta2y	0.4
Ch YTD	42.06
High	58.85
High52	58.85
High52 Date	2026-05-08
High52ch	-0.42%
Low	56.83
Low52	24.85
Low52 Date	2025-05-15
Low52ch	135.82%
Ma50ch	22.62%
Price vs 200-day SMA	42.45%
RSI	72.34
RSI Monthly	85.52
RSI Weekly	73.73
Sharpe ratio	1.92x
Sortino ratio	3.66
Total Return	-11.98%
Tr YTD	42.06
Tr1m	19.74%
Tr1w	6.03%
Tr3m	35.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	4
Analyst Price Target Top	$61.75
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.16
Earnings EPS Estimate Growth	45.45
Earnings Revenue Estimate	205,593,152x
Earnings Revenue Estimate Growth	49.21x
Operating Income	$93.2M
Operating Income Growth Q	120.5
Operating Income Growth3 Y	62.07
Operating margin	12.36
Price target	$60.86
Price Target Change	$3.86
Price Target Change Top	$5.38

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	40,291,261%
Float Percent	52.37%
Shares Insiders	4.56%
Shares Institutions	60.06%
Shares Out	76,938,016
Shares Qo Q	1.03%
Shares Yo Y	11.98%
Short Float	10.16%
Short Ratio	6.87
Short Shares	5.32

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$124.9M
Average Volume	912,166.8x
Bv Per Share	8.22
CAPEX	$-1.6M
Ch1m	19.74
Ch1w	6.03
Ch1y	118.9
Ch3m	35.99
Ch3y	328.1
Ch5y	300.5
Ch6m	52.72
Change	2.93%
Change From Open	2.7
Close	56.93
Days Gap	0.23
Depreciation Amortization	1,677,000
Dollar Volume	23,104,690.8
Earnings Date	2026-04-28
Earnings Time	bmo
EBIT	$93.2M
EBITDA	$94.9M
EPS	$0.91
F Score	7
FCF	$164.2M
FCF EV Yield	4.06x
FCF Per Share	$2.13
Financing CF	36,328,000
Fiscal Year End	December
Founded	2,015
Graham Number	12.95621
Graham Upside	-77.89
Income Tax	$32.9M
Investing CF	-169,368,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-28
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Lynch Fair Value	$4.54
Lynch Upside	-92.26
Ma150	43.48
Ma150ch	34.77%
Ma20	49.59
Ma20ch	18.18%
Net CF	32,820,000
Next Earnings Date	2026-07-28
Open	57.06
Optionable	Yes
P FCF Ratio	27.45
P OCF Ratio	27.18
Position In Range	87.62
Ppne	11,320,000
Price Date	2026-05-08
Price EBITDA	$47.51
Ptbv Ratio	7.63
Relative Volume	0.43x
Revenue	754,045,000x
SBC By Revenue	5.21x
Share Based Comp	39,311,000
Tax By Revenue	4.37x
Tax Rate	31.07%
Tr6m	52.72%
Volume	394,278
Z Score	8.44

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KNSA pay a dividend?

Capital-return profile for this ticker.

Performance

KNSA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KNSA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+60.1%

Float: +52.4% of shares outstanding

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KNSA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

72.3

Above 70: short-term overbought

Price vs 200-day MA

+42.4%

50/200-day relationship not available

Beta (5Y)

0.17

Less volatile than the market

Sharpe ratio

1.92

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KNSA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KNSA stock rating?

Kiniksa Pharmaceuticals International, plc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KNSA analysis?

The full report lives at /stocks/KNSA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KNSA?

The latest report frames KNSA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KNSA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.